True Drinks (TRUU) versus MediWound (MDWD) Financial Analysis

MediWound (NASDAQ: MDWD) and True Drinks (OTCMKTS:TRUU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for MediWound and True Drinks, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediWound 0 0 5 0 3.00
True Drinks 0 0 0 0 N/A

MediWound presently has a consensus target price of $10.00, indicating a potential upside of 50.38%. Given MediWound’s higher possible upside, equities research analysts plainly believe MediWound is more favorable than True Drinks.

Earnings and Valuation

This table compares MediWound and True Drinks’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound $2.50 million 71.95 -$22.14 million ($0.62) -10.73
True Drinks $2.58 million 1.01 -$5.44 million N/A N/A

True Drinks has higher revenue and earnings than MediWound.


This table compares MediWound and True Drinks’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MediWound -904.12% -226.62% -36.64%
True Drinks -165.55% -476.68% -141.06%

Insider and Institutional Ownership

32.8% of MediWound shares are owned by institutional investors. 10.1% of True Drinks shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

MediWound has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, True Drinks has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.


MediWound beats True Drinks on 6 of the 11 factors compared between the two stocks.

About MediWound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

About True Drinks

True Drinks Holdings, Inc. develops, markets, sells, and distributes naturally flavored water in the United States. The company offers AquaBall Naturally Flavored Water, a vitamin-enhanced and naturally flavored water drink. It also markets and distributes Bazi All Natural Energy, a liquid nutritional supplement drink. True Drinks Holdings, Inc. distributes its products through various retail channels, such as grocery stores, mass merchandisers, drug stores, and convenience stores, as well as through online retailers. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with's FREE daily email newsletter.

Leave a Reply